This international , randomised , double-blind , placebo-controlled , phase 3 study enrolled adults aged 18-55 years with relapsing multiple sclerosis , one or more relapse in the previous 12 months or two or more in the previous 24 months but no relapse in the previous 30 days , and an Expanded Disability Status Scale ( EDSS ) score of 5.5 points or less .